Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology

(2017) Josephine A. Touma et al.   Translational Cancer Research

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma

(2016) Jennifer L. Beaumont et al.   CANCER

Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors

(2014) Megumi Inada-Inoue et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

(2014) M H M Diekstra et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) B. Escudier et al.   ANNALS OF ONCOLOGY

Cytochrome P450 variations in different ethnic populations

(2012) Joseph McGraw et al.   Expert Opinion on Drug Metabolism & Toxicology

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology

(2012) Nagahiro Saijo   YONSEI MEDICAL JOURNAL

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma

(2012) Michael K. Wong et al.   JOURNAL OF MEDICAL ECONOMICS

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

(2011) Jenny J. Kim et al.   CANCER

Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development

(2011) Kouichi Kurose et al.   Drug Metabolism and Pharmacokinetics

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

(2011) Ateesha F. Mohamed et al.   PHARMACOECONOMICS

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma

(2010) T. Mizuno et al.   ANNALS OF ONCOLOGY

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

(2010) C-F Xu et al.   BRITISH JOURNAL OF CANCER

Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma

(2010) Chun-Fang Xu et al.   JOURNAL OF HEPATOLOGY

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

(2009) R Kumar et al.   BRITISH JOURNAL OF CANCER

Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy

(2009) P. H. O'Donnell et al.   CLINICAL CANCER RESEARCH

Ethnic differences in drug metabolism and toxicity from chemotherapy

(2009) Viet Hong Phan et al.   Expert Opinion on Drug Metabolism & Toxicology

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

(2009) Kuniaki Shirao et al.   INVESTIGATIONAL NEW DRUGS

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY